CD1d activation and blockade: A new antitumor strategy

Journal of Immunology

Volumn 182, Issue 6, 2009, Pages 3366-3371

  Teng, Michele W L ^a,c   Yue, Simon ^b   Sharkey, Janelle ^a   Exley, Mark A ^b   Smyth, Mark J ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; BLOCKING ANTIBODY; GROWTH INHIBITOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; IMMUNOREGULATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD1D; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; GROWTH INHIBITORS; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, SCID; NATURAL KILLER T-CELLS;

EID: 65449146344     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802964     Document Type: Article

References (35)

1. Palucka, A. K., H. Ueno, J. W. Fay, and J. Banchereau. 2007. Taming cancer by inducing immunity via dendritic cells. Immunol. Rev. 220: 129-150.
2. Steinman, R. M., and H. Hemmi. 2006. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311: 17-58.
3. Steinman, R. M. 2006. Linking innate to adaptive immunity through dendritic cells. Novartis Found. Symp. 279: 101-109.
4. + natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol. Rev. 220: 183-198.
5. Degli-Esposti, M. A., and M. J. Smyth. 2005. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5: 112-124.
6. Gabrilovich, D. 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4: 941-952.
7. Tong, A. W., and M. J. Stone. 2003. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 10: 1-13.
8. Lynch, D. H., A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller, and J. C. Schuh. 1997. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3: 625-631.
9. Swann, J. B., J. M. Coquet, M. J. Smyth, and D. I. Godfrey. 2007. CD1-restricted T cells and tumor immunity. Curr. Top. Microbiol. Immunol. 314: 293-323.
10. Vonderheide, R. H., J. P. Dutcher, J. E. Anderson, S. G. Eckhardt, K. F. Stephans, B. Razvillas, S. Garl, M. D. Butine, V. P. Perry, R. J. Armitage, R. Ghalie, D. A. Caron, and J. G. Gribben. 2001. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19: 3280-3287.
11. Vonderheide, R. H., K. T. Flaherty, M. Khalil, M. S. Stumacher, D. L. Bajor, N. A. Hutnick, P. Sullivan, J. J. Mahany, M. Gallagher, A. Kramer, et al. 2007. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25: 876-883.
12. Chiodoni, C., M. Iezzi, C. Guiducci, S. Sangaletti, I. Alessandrini, C. Ratti, F. Tiboni, P. Musiani, D. N. Granger, and M. P. Colombo. 2006. Triggering CD40 on endothelial cells contributes to tumor growth. J. Exp. Med. 203: 2441-2450.
13. Dhodapkar, M. V., M. D. Geller, D. H. Chang, K. Shimizu, S. Fujii, K. M. Dhodapkar, and J. Krasovsky. 2003. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197: 1667-1676.
14. Hong, C., and S. H. Park. 2007. Application of natural killer T cells in antitumor immunotherapy. Crit. Rev. Immunol. 27: 511-525.
15. Tahir, S. M., O. Cheng, A. Shaulov, Y. Koezuka, G. J. Bubley, S. B. Wilson, S. P. Balk, and M. A. Exley. 2001. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J. Immunol. 167: 4046-4050.
16. Dougan, S. K., A. Kaser, and R. S. Blumberg. 2007. CD1 expression on antigenpresenting cells. Curr. Top. Microbiol. Immunol. 314: 113-141.
17. Yue, S. C., A. Shaulov, R. Wang, S. P. Balk, and M. A. Exley. 2005. CD1d ligation on human monocytes directly signals rapid NF-κB activation and production of bioactive IL-12. Proc. Natl. Acad. Sci. USA 102: 11811-11816.
18. Terabe, M., J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D. I. Godfrey, S. Ostrand-Rosenberg, M. J. Smyth, and J. A. Berzofsky. 2005. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202: 1627-1633.
19. Smyth, M. J., K. Y. Thia, S. E. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. Kawano, S. B. Pelikan, N. Y. Crowe, and D. I. Godfrey. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191: 661-668.
20. + regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA 102: 9253-9257.
21. Exley, M. A., and M. J. Koziel. 2004. To be or not to be NKT: natural killer T cells in the liver. Hepatology 40: 1033-1040.
22. Terabe, M., and J. A. Berzofsky. 2007. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 28: 491-496.
23. Takeda, K., N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa, J. E. Tanner, T. J. Sayers, N. Seki, K. Okumura, H. Yagita, and M. J. Smyth. 2004. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199: 437-448.
24. Cretney, E., K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168: 1356-1361.
25. Koebel, C. M., W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. Smyth, and R. D. Schreiber. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907.
26. Smyth, M. J., N. Y. Crowe, and D. I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13: 459-463.
27. Trinchieri, G. 1998. Proinflammatory and immunoregulatory functions of interleukin-12. Int. Rev. Immunol. 16: 365-396.
28. Reis e Sousa, C., S. D. Diebold, A. D. Edwards, N. Rogers, O. Schulz, and R. Sporri. 2003. Regulation of dendritic cell function by microbial stimuli. Pathol. Biol. 51: 67-68.
29. Dzionek, A., Y. Inagaki, K. Okawa, J. Nagafune, J. Rock, Y. Sohma, G. Winkels, M. Zysk, Y. Yamaguchi, and J. Schmitz. 2002. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum. Immunol. 63: 1133-1148.
30. Xing, Z. 2000. Current understanding of macrophage type 1 cytokine responses during intracellular infections. Histol. Histopathol. 15: 199-205.
31. Terabe, M., S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752.
32. Durante-Mangoni, E., R. Wang, A. Shaulov, Q. He, I. Nasser, N. Afdhal, M. J. Koziel, and M. A. Exley. 2004. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J. Immunol. 173: 2159-2166.
33. Terabe, M., C. Khanna, S. Bose, F. Melchionda, A. Mendoza, C. L. Mackall, L. J. Helman, and J. A. Berzofsky. 2006. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-β. Cancer Res. 66: 3869-3875.
34. Renukaradhya, G. J., M. A. Khan, M. Vieira, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz. 2008. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 111: 5637-5645.
35. Kim, J. H., E. Y. Choi, and D. H. Chung. 2007. Donor bone marrow type II (non-Vα14Jα18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-γ and IL-4. J. Immunol. 179: 6579-6587.